Pediatric hepatocellular carcinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:33402OMIM:114550C22.0
Who is this for?
Show terms as
3FDA treatments12Active trials39Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Pediatric hepatocellular carcinoma (also called childhood liver cancer or pediatric HCC) is a rare but serious cancer that starts in the main cells of the liver, called hepatocytes. It is the most common type of primary liver cancer in children and teenagers, though it is still much rarer in children than in adults. The liver is a vital organ that filters the blood, helps digest food, and removes toxins from the body. When cancer develops in the liver, it can interfere with all of these important functions. Children with pediatric HCC often have an underlying liver condition that has been present since birth or early childhood, such as hepatitis B infection, certain metabolic liver diseases, or cirrhosis (scarring of the liver). Common symptoms include a swollen or painful belly, unexplained weight loss, nausea, yellowing of the skin or eyes (jaundice), and extreme tiredness. Some children have no symptoms early on, which can make the cancer harder to catch. Treatment usually involves a combination of surgery to remove the tumor, chemotherapy drugs, and sometimes a liver transplant. The outlook depends heavily on how early the cancer is found and whether it can be fully removed. When caught early and treated aggressively, some children can be cured. Research into new treatments, including targeted therapies and immunotherapy, is ongoing and offering new hope for families.

Also known as:

Key symptoms:

Swollen or bloated bellyA lump or mass that can be felt in the upper right side of the abdomenBelly pain or discomfortUnexplained weight lossLoss of appetiteNausea and vomitingExtreme tiredness or fatigueYellowing of the skin or whites of the eyes (jaundice)Pale or clay-colored stoolsDark urineFever without a clear causeSlowed growth or failure to thrive in younger children

Clinical phenotype terms (9)— hover any for plain English
Elevated circulating alpha-fetoprotein concentrationHP:0006254Hepatic necrosisHP:0002605Portal vein thrombosisHP:0030242Epigastric painHP:0410019
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Jan 2026Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection

West China Hospital

TrialRECRUITING
Aug 2024TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery

Medical University of Warsaw — NA

TrialRECRUITING
May 2024Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Baylor College of Medicine — PHASE1

TrialRECRUITING
Jan 2024TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.

Zhongda Hospital

TrialRECRUITING
Oct 2023The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers

National Taiwan University Hospital — NA

TrialACTIVE NOT RECRUITING
Feb 2023Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

Beijing Hospital — NA

TrialRECRUITING
Oct 2022BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Sotio Biotech Inc. — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Jun 2022Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

University of Colorado, Denver

TrialRECRUITING
Aug 2021Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Baylor College of Medicine — PHASE1

TrialACTIVE NOT RECRUITING
Apr 2021A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients

University Medical Center Groningen — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

3 available

Tecentriq and Avastin

atezolizumab + bevacizumab· Genentech, Inc.

TECENTRIQ, in combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy

Lipiodol

ethiodized oil injection· Guerbet LLC■ Boxed WarningOrphan Drug

Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)

Nexavar

sorafenib· Bayer HealthCare Pharmaceuticals, Inc.Orphan Drug

Treatment of unresectable hepatocellular carcinoma

Clinical Trials

12 recruitingView all trials with filters →
Phase 22 trials
A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients
Phase 2
Actively Recruiting
PI: M W Nijkamp, MD PhD (University Medical Center Groningen) · Sites: Groningen · Age: 1899 yrs
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Phase 2
Active
PI: Tim F Greten, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 18120 yrs
Phase 12 trials
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Phase 1
Actively Recruiting
PI: Andras Heczey, MD (Baylor College of Medicine) · Sites: Houston, Texas · Age: 121 yrs
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Phase 1
Active
PI: David Steffin, MD (Baylor College of Medicine) · Sites: Houston, Texas · Age: 121 yrs
N/A3 trials
Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
N/A
Actively Recruiting
PI: Jie Ma, Doctor (Beijing Hospital) · Sites: Beijing, Beijing Municipality · Age: 1875 yrs
TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery
N/A
Actively Recruiting
PI: Karolina Grąt, PhD (Medical University of Warsaw) · Sites: Warsaw, Masovian Voivodeship · Age: 1880 yrs
The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers
N/A
Active
· Sites: Taipei · Age: 2099 yrs
Other4 trials
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Actively Recruiting
PI: Gaojun Teng, M.D. (Zhongda Hospital) · Sites: Nanjing, Jiangsu · Age: 1899 yrs
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Actively Recruiting
PI: Ana Gleisner, MD (University of Colorado, Denver) · Sites: Aurora, Colorado · Age: 1899 yrs
Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
Actively Recruiting
· Sites: Chengdu, Sichuan · Age: 1880 yrs
Extracellular RNA Markers of Liver Disease and Cancer
Active
PI: Tushar Patel, MBChB (Mayo Clinic) · Sites: Jacksonville, Florida; Chicago, Illinois +2 more · Age: 1899 yrs

Specialists

Showing 25 of 39View all specialists →
GT
Gregory M Tiao
PALO ALTO, CA
Specialist
PI on 1 active trial7 Pediatric hepatocellular carcinoma publications
AP
AeRang Kim, MD, PhD
BETHESDA, MD
Specialist
PI on 7 active trials
AM
Allison O'Neill, MD
Specialist
PI on 3 active trials1 Pediatric hepatocellular carcinoma publication
AM
AeRang Kim, MD
BETHESDA, MD
Specialist
PI on 2 active trials1 Pediatric hepatocellular carcinoma publication
CM
Colleen Annesley, MD
SEATTLE, WA
Specialist
PI on 5 active trials
RI
Renuka Iyer
BUFFALO, NY
Specialist
PI on 3 active trials33 Pediatric hepatocellular carcinoma publications
LS
Lauren Van Scoy
Specialist
PI on 1 active trial
ME
Mattias Ekstedt
Specialist
PI on 1 active trial
RF
Ryan C Fields
Specialist
PI on 1 active trial
CC
Clara Curiel-Lewandroski
Specialist
PI on 1 active trial
HM
Hironobu Minami
Specialist
PI on 1 active trial
SC
Shao-Bin Cheng
Specialist
PI on 1 active trial
LC
Laura Crocetti
Specialist
PI on 1 active trial
SM
Sara Mijwel
Specialist
PI on 1 active trial
XX
Xuhua Xuhua
Specialist
PI on 1 active trial
SS
Stephanie Sohl
Specialist
PI on 1 active trial
HV
Helena M Verkooijen
Specialist
PI on 1 active trial
SH
Samir M. Hanash
Specialist
PI on 1 active trial
YY
Yunfang Yu
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Tecentriq and Avastin(atezolizumab + bevacizumab)Genentech, Inc.

Yervoy

Bristol-Myers Squibb Company

Yervoy Patient Support (BMS Access Support)

Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to Pediatric hepatocellular carcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Pediatric hepatocellular carcinomaForum →

No community posts yet. Be the first to share your experience with Pediatric hepatocellular carcinoma.

Start the conversation →

Latest news about Pediatric hepatocellular carcinoma

No recent news articles for Pediatric hepatocellular carcinoma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my child's cancer, and what does that mean for treatment options?,Is surgery or a liver transplant possible for my child, and what are the chances of a cure?,Are there clinical trials available that my child might qualify for?,Does my child have an underlying genetic or liver condition that caused this cancer, and should other family members be tested?,What are the short-term and long-term side effects of the chemotherapy drugs being recommended?,How will we monitor whether the treatment is working, and what happens if it stops working?,What support services — such as nutrition counseling, mental health support, or financial assistance — are available to our family?

Common questions about Pediatric hepatocellular carcinoma

What is Pediatric hepatocellular carcinoma?

Pediatric hepatocellular carcinoma (also called childhood liver cancer or pediatric HCC) is a rare but serious cancer that starts in the main cells of the liver, called hepatocytes. It is the most common type of primary liver cancer in children and teenagers, though it is still much rarer in children than in adults. The liver is a vital organ that filters the blood, helps digest food, and removes toxins from the body. When cancer develops in the liver, it can interfere with all of these important functions. Children with pediatric HCC often have an underlying liver condition that has been pre

At what age does Pediatric hepatocellular carcinoma typically begin?

Typical onset of Pediatric hepatocellular carcinoma is childhood. Age of onset can vary across affected individuals.

Are there clinical trials for Pediatric hepatocellular carcinoma?

Yes — 12 recruiting clinical trials are currently listed for Pediatric hepatocellular carcinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Pediatric hepatocellular carcinoma?

25 specialists and care centers treating Pediatric hepatocellular carcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Pediatric hepatocellular carcinoma?

2 patient support programs are currently tracked on UniteRare for Pediatric hepatocellular carcinoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.